New Zealand markets open in 8 hours 41 minutes

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
197.78-2.84 (-1.42%)
At close: 04:00PM EDT
198.63 +0.85 (+0.43%)
After hours: 07:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close200.62
Open200.28
Bid193.40 x 900
Ask202.71 x 900
Day's range194.46 - 200.62
52-week range187.16 - 291.54
Volume1,443,578
Avg. volume906,209
Market cap28.7B
Beta (5Y monthly)0.42
PE ratio (TTM)14.34
EPS (TTM)13.79
Earnings date18 Oct 2022 - 24 Oct 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est234.14
  • Financial Times

    Alzheimer’s drug trial brings pivotal test of maligned brain plaque theory

    A late-stage trial of an Alzheimer’s drug set to generate results within weeks is shaping up as a pivotal moment in a three-decade quest to prove that removing sticky amyloid plaques from the brain can slow down the disease. The phase 3 trial is being led by Eisai, a Tokyo-based pharmaceutical company that has partnered US biotech Biogen to develop lecanemab. Earlier studies suggested the monoclonal antibody treatment can clear plaques known as beta amyloid that are at the centre of an increasingly acrimonious scientific debate over what causes Alzheimer’s.

  • GlobeNewswire

    The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS

    Publication includes the Phase 3 VALOR SOD1-ALS trial and its open-label-extension study, underscoring the importance of these longer-term data12-month data show earlier initiation of tofersen slowed decline across critical measures of function and strength in people diagnosed with SOD1-ALSResults offer important learnings regarding the biology of SOD1-ALS and design of ALS clinical trials CAMBRIDGE, Mass., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that The Ne

  • Financial Times

    Biogen drug slows progress of motor neurone disease in landmark trial

    Tofersen targets a defective gene that causes about 2% of cases of MND, also known as amyotrophic lateral sclerosis